Abstract: The present disclosure is directed to positioning animated images within a dynamic keyboard interface. In particular, the methods and systems of the present disclosure can: receive, from a user device on which an application is executed, data indicating a context of: the application, and/or a dynamic keyboard interface provided in association with the application; identify, based at least in part on the data indicating the context, a plurality of different animated images, including an animated image comprising an advertisement, for presentation by the dynamic keyboard interface; communicate, to the user device, data indicating the plurality of different animated images; receive, from the user device, data indicating a selection of the animated image comprising the advertisement; and determine, based at least in part on the data indicating the selection and the data indicating the context, a position within the dynamic keyboard interface for presenting the animated image comprising the advertisement.

Abstract: A solenoid valve can include a valve body and an actuator. The actuator can include an actuator housing, a coil disposed in the actuator housing and a core tube extending from the valve body through and beyond the actuator housing when the actuator is properly installed on the valve body. A monitoring assembly can include a target on the core tube and a detector configured to detect the target when the actuator is properly installed on the valve body and/or core tube.

Abstract: Provided are sorafenib hemi-tosylate, polymorphs thereof, polymorphs of sorafenib tosylate, preparation thereof and pharmaceutical compositions thereof.

Abstract: The present invention provides crystalline forms of Palonosetron hydrochloride, processes for their preparation and pharmaceutical compositions containing such crystalline forms of Palonosetron HCl.

Abstract: Provided are polymorphs of fluticasone furoate and processes for preparation thereof.

Abstract: The present invention provides polymorphs of Sunitinib base and processes for preparation thereof.

Abstract: Processes useful in the preparation of pharmaceutical compounds such as fulvestrant and processes for the preparation of fulvestrant.

Abstract: Methods for preparing sunitinib or salts thereof are described using novel intermediates and chemical pathways.

Abstract: Provided are polymorphs of fluticasone furoate and processes for preparation thereof.

Abstract: The invention provides a high-yield process for the preparation of letrozole having a high purity, without the need for removal of the 4-[1-(1,3,4-triazolyl)methyl]benzonitrile impurity at the intermediate stage. The invention also provides a process for the synthesis of letrozole in which formation of the impurity 4-[1-(1,3,4-triazolyl)methyl]benzonitrile during the first stage is minimized. In the process, a 4-(halomethyl)benzonitrile is reacted with a salt of 1H-1,2,4-triazole, reducing the formation of the impurity. Preferably, the preparation is conducted as a one-pot process.

Abstract: The present invention provides crystalline forms of Palonosetron hydrochloride, processes for their preparation and pharmaceutical compositions containing such crystalline forms of Palonosetron HCl.

Abstract: Processes useful in the preparation of pharmaceutical compounds such as fulvestrant and processes for the preparation of fulvestrant.

Abstract: Processes useful in the preparation of pharmaceutical compounds such as fulvestrant and processes for the preparation of fulvestrant.

Abstract: Methods for the synthesis of the N-carbamoyl imidazole (I) and its 1:1 adduct with imidazole are provided. Methods for the preparation of these crystalline intermediates in a high state of purity are also provided. These intermediates react cleanly under mild conditions to produce sorafenib in high yield and purity, without generating difficult-to-remove impurities.

Abstract: Methods for preparing sunitinib or salts thereof are described using novel intermediates and chemical pathways.

Abstract: The present application relates to an improved process for the preparation of capecitabine.

Abstract: Provided are sorafenib hemi-tosylate, polymorphs thereof, polymorphs of sorafenib tosylate, preparation thereof and pharmaceutical compositions thereof.

Abstract: A phase locked magnetron comprises a cathode and anode and an interaction space in between. The cathode is coupled to an injected locking signal, which prompts the operation of the magnetron to be in phase with the phase of the locking signal. From a magnetron of the type in which the cathode is at a large negative potential, the coupling to the locking signal is by non-contact means, in particular, by extending the cathode into a waveguide in which the locking signal is present. An alternative arrangement is for a magnetron of the type in which the cathode is substantially at ground potential. In this arrangement the coupling is by direct electrical connection to a conductor having the injected locking signal.

Abstract: This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration of fludarabine phosphate in the composition may be between about 0.5 mg/mL and about 50 mg/mL. The pH of the composition may be between about 5.5 and about 7.1.

Abstract: This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration of fludarabine phosphate in the composition may be between about 0.5 mg/mL and about 50 mg/mL. The pH of the composition may be between about 5.5 and about 7.1.